Free Newsletter
Docs prefer virtual reps to living ones
Assembly-line workers fear being replaced by robots. Now pharma reps can fear losing their places to the Internet. According to a study by Verispan, 47 percent of docs thought they got as much info from e-promotions as face-to-face detailing by reps, and 21 percent thought it was better than the real, live thing.
That's why 10 percent last year opted for electronic detailing instead of in-person rep visits, when they had the choice. "Physicians prefer this form of detailing because they can do the activities on their own...they can learn about the drugs without disrupting patient time with reps in the office," said a Verispan manager.
Another note: Newer docs were most likely to switch to online detailing. Understandable, considering that the younger generation tends to be more comfortable with technology. But that just means that as more and more new docs come on the scene, the proportion of them who prefer interacting with virtual reps rather than real ones is likely to grow.
- read the item at Pharma Marketing Blog
- see the PharmaExec report
Related Articles:
Ranks of sales reps thinning. Sales rep report
Study: Drug ads drown in online noise. Ad report
Docs go cold turkey on industry pay. Report
Dr. Drug Rep tells all. Sales rep report
Comments
anyone with experience in the field will tell you that doctors will always choose other activities over learning about new therapies unless there is someone there speaking to them. Doctors say they prefer a lot of things, but when it's time to actually implement a change, they are notoriously resistant.
Earlier Medical Reps stuck to a company and Territory and built relationship with Physicians and could generate Prescriptions based on it. They could also gather Knowledge in a therapeutic segment and could discuss intelligebly with a doctor. Today there is lack of quality Reps and Physicians prefer virtual reps to access information on products. Pharma companies too find it more economical. This is going to be the order of the day.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





